Chinese authorities approve seasoned Novo Nordisk combination treatment
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13428023.ece/ALTERNATES/schema-16_9/20067398843395-1920x1079we.jpg)
The treatment Xultophy, which combines Novo Nordisk's long-acting insulin Tresiba with the GLP-1 analog Victoza, is now headed to the Chinese market.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
WHO adds Novo Nordisk insulin to essential medicine lists
For subscribers